Asia Pacific Branded Generics Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Asia Pacific Branded Generics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Asia Pacific Branded Generics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising Adoption of Branded Generics owing to their Affordability to Favor Market
5.1.2 Spurring government initiatives for the development of branded generics augmenting the market growth

5.2 Market Opportunities

5.2.1 Loss of Patent Exclusivity of Branded drugs and Emergence of Biosimilars Brings Future Opportunities

5.3 Future Trends

5.3.1 Utilization of Branded Generics by Healthcare Providers and Professionals

5.4 Impact of Drivers and Restraints

6. Asia Pacific Branded Generics Market Regional Analysis

6.1 Asia Pacific Branded Generics Market Overview

6.2 Asia Pacific Branded Generics Market Revenue 2020-2028 (US$ Billion)

6.3 Asia Pacific Branded Generics Market Forecast Analysis

7. Asia Pacific Branded Generics Market Analysis – by Therapeutic Application

7.1 Oncology

7.1.1 Overview
7.1.2 Oncology: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.2 Cardiovascular Diseases

7.2.1 Overview
7.2.2 Cardiovascular Diseases: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.3 Diabetes

7.3.1 Overview
7.3.2 Diabetes: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.4 Neurology

7.4.1 Overview
7.4.2 Neurology: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.5 Gastrointestinal Diseases

7.5.1 Overview
7.5.2 Gastrointestinal Diseases: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.6 Dermatology Diseases

7.6.1 Overview
7.6.2 Dermatology Diseases: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

7.7 Analgesics and Anti-Inflammatory

7.7.1 Overview
7.7.2 Analgesics and Anti-Inflammatory: Asia Pacific Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)

8. Asia Pacific Branded Generics Market Analysis – by Distribution Channel

8.1 Hospitals

8.1.1 Overview
8.1.2 Hospitals: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.2 Retail Pharmacies

8.2.1 Overview
8.2.2 Retail Pharmacies: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.3 Online Pharmacies

8.3.1 Overview
8.3.2 Online Pharmacies: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.4 Drug Stores

8.4.1 Overview
8.4.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9. Asia Pacific Branded Generics Market Analysis – by Drug Class

9.1 Alkylating Agents

9.1.1 Overview
9.1.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.2 Antimetabolites

9.2.1 Overview
9.2.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.3 Hormones

9.3.1 Overview
9.3.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.4 Antihypertensive

9.4.1 Overview
9.4.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.5 Lipid-Lowering Drugs

9.5.1 Overview
9.5.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.6 Antidepressants

9.6.1 Overview
9.6.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.7 Antipsychotics

9.7.1 Overview
9.7.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.8 Antiepileptic

9.8.1 Overview
9.8.2 Drug Stores: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10. Asia Pacific Branded Generics Market – Asia-Pacific Analysis

10.1 Asia-Pacific

10.1.1 Asia Pacific Branded Generics Market Breakdown, by Key Country, 2023 and 2028 (%)
10.1.1.1 Asia Pacific Branded Generics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 China: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10.1.1.1.1 China: Asia Pacific Branded Generics Market Breakdown, by Therapeutic Application
10.1.1.1.2 China: Asia Pacific Branded Generics Market Breakdown, by Distribution Channel
10.1.1.1.3 China: Asia Pacific Branded Generics Market Breakdown, by Drug Class

10.1.1.2 India: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10.1.1.2.1 India: Asia Pacific Branded Generics Market Breakdown, by Therapeutic Application
10.1.1.2.2 India: Asia Pacific Branded Generics Market Breakdown, by Distribution Channel
10.1.1.2.3 India: Asia Pacific Branded Generics Market Breakdown, by Drug Class

10.1.1.3 Japan: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10.1.1.3.1 Japan: Asia Pacific Branded Generics Market Breakdown, by Therapeutic Application
10.1.1.3.2 Japan: Asia Pacific Branded Generics Market Breakdown, by Distribution Channel
10.1.1.3.3 Japan: Asia Pacific Branded Generics Market Breakdown, by Drug Class

10.1.1.4 Australia: Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10.1.1.4.1 Australia: Asia Pacific Branded Generics Market Breakdown, by Therapeutic Application
10.1.1.4.2 Australia: Asia Pacific Branded Generics Market Breakdown, by Distribution Channel
10.1.1.4.3 Australia: Asia Pacific Branded Generics Market Breakdown, by Drug Class

10.1.1.5 Rest of Asia-Pacific : Asia Pacific Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Branded Generics Market Breakdown, by Therapeutic Application
10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Branded Generics Market Breakdown, by Distribution Channel
10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Branded Generics Market Breakdown, by Drug Class

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Asia Pacific Branded Generics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Aspen Holdings

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 AstraZeneca

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bausch Health (Valeant Pharmaceuticals)

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Dr. Reddy's Laboratories Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 GlaxoSmithKline plc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Hetero

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Lupin

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Mylan N.V.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Par Pharmaceuticals

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Sandoz International Gmbh

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

13.11 Sanofi

13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments

13.12 Teva Pharmaceutical Industries Ltd.

13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments

14. Appendix

14.1 About Business Market Insights